These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 24766850

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Rivaroxaban and Dabigatran for Suppression of Mechanical Heart Valve-Induced Thrombin Generation.
    Jaffer IH, Fredenburgh JC, Stafford A, Whitlock RP, Weitz JI.
    Ann Thorac Surg; 2020 Aug; 110(2):582-590. PubMed ID: 31877292
    [Abstract] [Full Text] [Related]

  • 28. Factor Xa inhibition by rivaroxaban in the trough steady state can significantly reduce thrombin generation.
    Horinaka S, Sugawara R, Yonezawa Y, Ishimitsu T.
    Br J Clin Pharmacol; 2018 Jan; 84(1):79-87. PubMed ID: 28888219
    [Abstract] [Full Text] [Related]

  • 29. Drotrecogin alfa (activated, Xigris) in combination with heparin or melagatran: an in vitro investigation.
    Koestenberger M, Cvirn G, Gallistl S, Baier K, Leschnik B, Muntean W.
    J Thromb Thrombolysis; 2004 Aug; 18(1):5-10. PubMed ID: 15744547
    [Abstract] [Full Text] [Related]

  • 30. Dabigatran but not rivaroxaban or apixaban treatment decreases fibrinolytic resistance in patients with atrial fibrillation.
    Semeraro F, Incampo F, Ammollo CT, Dellanoce C, Paoletti O, Testa S, Colucci M.
    Thromb Res; 2016 Feb; 138():22-29. PubMed ID: 26826504
    [Abstract] [Full Text] [Related]

  • 31. The respective and combined anticoagulant effects of recombinant human activated protein C, melagatran and heparins using CAT.
    Cimenti C, Koestenberger M, Leschnik B, Haidl H, Muntean W.
    Thromb Res; 2007 Feb; 119(3):361-7. PubMed ID: 16712904
    [Abstract] [Full Text] [Related]

  • 32. Effects of the oral, direct factor xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity.
    Graff J, von Hentig N, Misselwitz F, Kubitza D, Becka M, Breddin HK, Harder S.
    J Clin Pharmacol; 2007 Nov; 47(11):1398-407. PubMed ID: 17873238
    [Abstract] [Full Text] [Related]

  • 33. Beyond unfractionated heparin and warfarin: current and future advances.
    Hirsh J, O'Donnell M, Eikelboom JW.
    Circulation; 2007 Jul 31; 116(5):552-60. PubMed ID: 17664384
    [No Abstract] [Full Text] [Related]

  • 34. In vitro assessment, using thrombin generation, of the applicability of prothrombin complex concentrate as an antidote for Rivaroxaban.
    Dinkelaar J, Molenaar PJ, Ninivaggi M, de Laat B, Brinkman HJ, Leyte A.
    J Thromb Haemost; 2013 Jun 31; 11(6):1111-8. PubMed ID: 23578206
    [Abstract] [Full Text] [Related]

  • 35. Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.
    Graff J, Harder S.
    Clin Pharmacokinet; 2013 Apr 31; 52(4):243-54. PubMed ID: 23389892
    [Abstract] [Full Text] [Related]

  • 36. Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro.
    Perzborn E, Heitmeier S, Laux V, Buchmüller A.
    Thromb Res; 2014 Apr 31; 133(4):671-81. PubMed ID: 24529498
    [Abstract] [Full Text] [Related]

  • 37. The effect of aprotinin on activated protein C-mediated downregulation of endogenous thrombin generation.
    Tanaka KA, Szlam F, Levy JH.
    Br J Haematol; 2006 Jul 31; 134(1):77-82. PubMed ID: 16803571
    [Abstract] [Full Text] [Related]

  • 38. Anticoagulant action of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, in umbilical cord and adult plasma: an in vitro examination.
    Koestenberger M, Gallistl S, Cvirn G, Baier K, Leschnik B, Muntean W.
    Thromb Res; 2005 Jul 31; 115(1-2):135-42. PubMed ID: 15567465
    [Abstract] [Full Text] [Related]

  • 39. Drotrecogin alfa activated (recombinant human activated protein C) in combination with heparin or melagatran: effects on prothrombin time and activated partial thromboplastin time.
    Koestenberger M, Cvirn G, Gallistl S, Muntean W.
    Blood Coagul Fibrinolysis; 2004 Oct 31; 15(8):693-7. PubMed ID: 15613925
    [Abstract] [Full Text] [Related]

  • 40. The effect of total hip/knee replacement surgery and prophylactic dabigatran on thrombin generation and coagulation parameters.
    Green L, Lawrie AS, Patel R, Stephens RC, Mackie IJ, Chitolie A, Haddad FS, Machin SJ.
    Thromb Res; 2012 Nov 31; 130(5):775-9. PubMed ID: 22245224
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.